AW: [HSF] Percutaneous Valves

[Donald Ross]

Roberto,
What on earth is the indication for this procedure.
I am sure you have equally excellent results with AVR, in really  
awful cases, as the rest of us.
Mortality is ~2% so how can a surgeon accept 10%?
Don
On 02/02/2007, at 2:09 PM, Dr. Roberto Battellini wrote:

> Ben,
> in Leipzig one of our Surgeons (Thomas Walther )has done 30 cases via
> transapical with 3 deaths. He also assists the cardiologists to put  
> them
> transfemoral.
> The new number (January 2007) of Eur Jour Cardioth Surg  is  
> dedicated fully
> to this technique and he writes there his experience.
> Roberto
>
> -----Ursprüngliche Nachricht-----
> Von: openheart-l-bounces at lists.hsforum.com
> [mailto:openheart-l-bounces at lists.hsforum.com] Im Auftrag von Ben  
> Bidstrup
> Gesendet: Donnerstag, 1. Februar 2007 22:32
> An: HS Forum
> Betreff: [HSF] Percutaneous Valves
>
> http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2007/01/31/ 
> nhealth31.xm
> l
>
> Here is a slightly concerning article if it heralds yet another of
> our areas being condemned to the cath lab with ? results.
>
>
> -- 
> Ben Bidstrup FRACS FRCSEd FEBCTS
> Consultant Cardiothoracic Surgeon
> _______________________________________________
> OpenHeart-L mailing list
>
> Send postings to:
>  OpenHeart-L at lists.hsforum.com
>
> To UNSUBSCRIBE, to CHANGE email address, or to view archives:
> http://mmp.cjp.com/mailman/listinfo/openheart-l
>
> All messages transmitted by the OpenHeart-L are subject to the  
> policies and
> disclaimers posted at:
> http://www.hsforum.com/listdisclaim
> -----------------------------------------
>
> _______________________________________________
> OpenHeart-L mailing list
>
> Send postings to:
>  OpenHeart-L at lists.hsforum.com
>
> To UNSUBSCRIBE, to CHANGE email address, or to view archives:
> http://mmp.cjp.com/mailman/listinfo/openheart-l
>
> All messages transmitted by the OpenHeart-L are subject to the  
> policies and
> disclaimers posted at:
> http://www.hsforum.com/listdisclaim
> -----------------------------------------